Back to top
more

CytomX Therapeutics (CTMX)

(Real Time Quote from BATS)

$2.22 USD

2.22
1,125,231

-0.15 (-6.33%)

Updated Aug 6, 2025 02:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

CytomX Therapeutics (CTMX) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 50% and 43.36%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

SpringWorks Therapeutics (SWTX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

SpringWorks Therapeutics (SWTX) delivered earnings and revenue surprises of -37.04% and 23.53%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Caribou Biosciences (CRBU) delivered earnings and revenue surprises of 0% and 5.88%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ANI Pharmaceuticals to Report Q1 Earnings: Is a Beat in the Cards?

by Zacks Equity Research

ANIP's first-quarter 2025 revenues are likely to have been driven by increased sales of its lead product, Cortrophin Gel, and other rare disease products.

Zacks Equity Research

Perrigo to Report Q1 Earnings: Is a Beat in Store for the Stock?

by Zacks Equity Research

PRGO's first-quarter top line is likely to have been impacted by exited businesses and product lines, and unfavorable currency movements.

Zacks Equity Research

Novavax to Report First-Quarter Earnings: Is a Beat in Store?

by Zacks Equity Research

On NVAX's first-quarter earnings call, investors will likely focus on pipeline updates.

Zacks Equity Research

BioMarin's First-Quarter Earnings & Sales Beat Estimates

by Zacks Equity Research

BMRN reports encouraging first-quarter results. The company reiterates its financial guidance for 2025.

Zacks Equity Research

Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Guardant Health (GH) delivered earnings and revenue surprises of 19.67% and 6.47%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Corcept Therapeutics to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On CORT's first-quarter 2025 earnings call, investors are likely to focus on the sales performance of its Cushing's syndrome drug, Korlym.

Zacks Equity Research

Vertex Gears Up to Report Q1 Earnings: Is a Beat in the Cards?

by Zacks Equity Research

On VRTX's first-quarter earnings call, investors are likely to focus on the launch preparation for Alyftrek (vanza triple) and Journavx (suzetrigine).

Zacks Equity Research

GSK to Report First-Quarter Earnings: Is a Beat in Store?

by Zacks Equity Research

We expect GSK's specialty products like Cabenuva, Juluca, Dovato, Nucala, Ojjaara, Jemperli and Trelegy Ellipta to have driven first-quarter sales performance.

Zacks Equity Research

Zoetis Gears Up to Report Q1 Earnings: Here's What to Expect

by Zacks Equity Research

ZTS' higher companion animal product sales are likely to have driven revenues in first-quarter 2025 in both the United States and International segments.

Zacks Equity Research

CRISPR Therapeutics to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On CRSP's first-quarter 2025 earnings call, investors will likely focus on the sales numbers of its new gene therapy, Casgevy.

Zacks Equity Research

Can Moderna Keep the Beat Streak Alive This Earnings Season?

by Zacks Equity Research

When MRNA reports first-quarter earnings, investors will likely focus on pipeline updates.

Zacks Equity Research

Recursion Pharmaceuticals to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

RXRX is expected to provide updates on its oncology and rare disease clinical-stage pipeline in its first-quarter 2025 earnings release, given the absence of a marketed product.

Zacks Equity Research

CytomX Gears Up to Report Q1 Earnings: Here's What to Expect

by Zacks Equity Research

On the Q1 2025 earnings call, investors can expect updates regarding the progress in the development of CTMX's lead candidate, CX-2051, for colorectal cancer.

Zacks Equity Research

Beam Therapeutics to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

In the absence of any marketed drugs, investors are set to focus on BEAM's pipeline updates when it reports first-quarter 2025 earnings.

Zacks Equity Research

Merck Q1 Earnings & Sales Beat Estimates, '25 EPS Outlook Cut

by Zacks Equity Research

MRK posts better-than-expected first-quarter results but trims its 2025 EPS outlook due to anticipated one-time charges.

Zacks Equity Research

Viking Therapeutics Q1 Loss Wider Than Expected, Sales Nil, Stock Dips

by Zacks Equity Research

VKTX's first-quarter earnings miss estimates. The company remains on track to start the late-stage development of its obesity injection before June-end.

Zacks Equity Research

Amicus Therapeutics to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On FOLD's first-quarter 2025 earnings call, investors are likely to focus on the sales of lead drug Galafold and the combo drug, Pombiliti + Opfolda.

Zacks Equity Research

Incyte Gears Up to Report Q1 Earnings: Here's What You Should Know

by Zacks Equity Research

INCY is likely to beat Q1 earnings estimates, primarily driven by increased U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi.

Zacks Equity Research

Verastem Oncology to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Devoid of any marketed drugs, investors are set to focus on VSTM's pipeline updates when it reports first-quarter 2025 earnings.

Zacks Equity Research

Viking Therapeutics to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Devoid of marketed drugs, investors will focus on VKTX's pipeline updates when it reports first-quarter earnings.

Zacks Equity Research

SRPT Provides Pipeline Updates on Rare Muscular Disorder Therapies

by Zacks Equity Research

Following positive FDA feedback, Sarepta advances a fourth LGMD program to clinical development.

Zacks Equity Research

VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study

by Zacks Equity Research

Valneva intends to test its experimental Shigella vaccine in nearly 110 infants. Results from this study are expected later this year.